BioCentury | Apr 25, 2016
Politics, Policy & Law

SCOTUS to the rescue?

...dalfampridine from Acorda [2] Diprivan propofol from Fresenius Kabi [1] Gattex teduglutide from Shire [2] Combigan...
BioCentury | Oct 5, 2015
Company News

Allergan, Ferrum Ferro Capital opthalmic news

...against Allergan. Ferrum’s petition targeted U.S. Patent No. 7,030,149, which covers a method of using Combigan...
...to inquiries concerning the status of the lawsuit and does not break out sales of Combigan...
BioCentury | Oct 1, 2015
Company News

Hedge fund's IPR petition against Allergan denied

...last week. Ferrum's petition targeted U.S. Patent No. 7,030,149, which covers a method of using Combigan...
BioCentury | Sep 14, 2015
Politics, Policy & Law

IPR battles

...7,932,268 8/19/27 3 12/10/19 8/28/15 $1.1M (0%) $3.1M (1%) 8,618,135 3/7/25 8/28/15 Allergan plc (NYSE:AGN) Combigan...
BioCentury | Jun 29, 2015
Company News

Allergan ophthalmic news

...with the U.S. Patent and Trademark Office challenging a claim on an Allergan patent covering Combigan...
...ocular hypertension. The challenged claim of U.S. Patent No. 7,030,149 covers a method of using Combigan...
...the patent, which expires in 2022, as valid. There are seven Orange Book-listed patents covering Combigan...
BioCentury | Jun 25, 2015
Company News

Allergan sues hedge fund in response to Combigan IPR

...with the U.S. Patent and Trademark Office challenging a claim on an Allergan patent covering Combigan...
...ocular hypertension. The challenged claim of U.S. Patent No. 7,030,149 covers a method of using Combigan...
...patent as valid. The patent expires in 2022. There are seven Orange Book-listed patents covering Combigan...
BioCentury | May 18, 2015
Politics, Policy & Law

Cut bait

...8,663,685 1/18/25 3 12/22/26 2/10/15 -$181.4M (11%) -$441.1M (26%) 8,007,826 5/26/27 2/27/15 Actavis plc (NYSE:ACT) Combigan...
BioCentury | Aug 19, 2013
Company News

Allergan ophthalmic news

...Appellate Board (IPAB) invalidated two patents held by Allergan for ophthalmic drugs Ganfort bimatoprost/timolol and Combigan...
...fixed-dose of 0.03% bimatoprost, a prostaglandin analog, and 0.5% timolol, a beta adrenenergic receptor inhibitor. Combigan...
...combination of 0.2% brimonidine, an alpha adrenergic receptor agonist, and timolol. Allergan markets Ganfort and Combigan...
BioCentury | Nov 5, 2007
Clinical News

Combigan regulatory update

...FDA approved AGN'S Combigan 0.2% brimonidine/0.5% timolol solution as an adjunctive or replacement therapy to reduce...
...therapy to reduce inadequately controlled intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Combigan...
...receptor agonist, and timolol, a beta adrenenergic receptor inhibitor. Allergan Inc. (AGN), Irvine, Calif. Product: Combigan...
BioCentury | Jan 1, 2007
Clinical News

Combigan regulatory update

...AGN received an FDA approvable letter for Combigan to reduce elevated intraocular pressure (IOP) in patients...
...questions. Combigan is a combination of brimonidine and timolol. Allergan Inc. (AGN), Irvine, Calif. Product: Combigan...
Items per page:
1 - 10 of 11